Views Article – Sharenet Wealth

Australasia, News

Australia shares rise on vaccine hopes, upbeat data

By Soumyajit Saha

July 2 (Reuters) – Australian shares were higher on Thursday, taking cues from a robust Wall Street session overnight on promising results from a coronavirus vaccine trial, and on encouraging data from top economy United States and largest trading partner China.

The S&P/ASX 200 index rose 0.47% to 5,962.4 in early trade.

Risk sentiment received a boost after a COVID-19 vaccine from pharmaceutical giant Pfizer and Germany’s BioNTech BNTX.O was found to be well tolerated in early-stage human trials, sending all three major U.S. indexes up between 0.3% and 0.9%.

Different sets of data from top two economies United States and China on Wednesday showed a rise in factory activity in both countries in June.

Further gains though were likely capped by a continued rise in coronavirus cases, with authorities on Wednesday saying they would lock down more than 300,000 people in suburbs near Melbourne to check a spike in infections.

Healthcare stocks gained over 1%, with Resmed Inc rising 1.8%.

Technology stocks advanced 2.6%, with Afterpay Ltd gaining 4.8% as brokerage Citi nearly tripled its price target on the company’s stocks and raised its estimates.

The energy subindex rose 0.7% on the back of overnight gains in oil prices following a drawdown in U.S. crude inventories, though prices later retreated.

Miners fell 0.8%, with global miners BHP Group and Rio Tinto down 0.9% and 0.6%, respectively, as ironore and steel prices fell overnight mirroring a slowdown in construction activities.

Gold stocks fell 1.03% as the yellow metal’s prices dropped from a near eight-year high amid positive economic data and vaccine hopes.

The number of issues on the ASX that advanced were 638 while 240 declined.

In New Zealand, the benchmark S&P/NZX 50 index rose 0.2% to 11,369.8, helped partly by utility stocks like Contact Energy, which rose 1.2%. (Reporting by Soumyajit Saha in Bengaluru; Editing by Shailesh Kuber)


© 2019 Thomson Reuters. All rights reserved. Reuters content is the intellectual property of Thomson Reuters or its third party content providers. Any copying, republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. "Reuters" and the Reuters Logo are trademarks of Thomson Reuters and its affiliated companies.